Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise study
We identified 7 species for which fecal abundances decreased with ETI and correlated with calprotectin decrease, supporting a close relationship between fecal microbiota and inflammation in PwCF. Future work will define these relationships with metabolites and GI symptoms during long-term ETI therapy.
Authors
- Steven M. Rowe (ORCID: https://orcid.org/0000-0001-9045-0133)
- Sarah Jane Schwarzenberg (ORCID: https://orcid.org/0000-0001-5077-7625)
- Andrea Kelly (ORCID: https://orcid.org/0000-0003-1724-9868)
- Hillary S. Hayden (ORCID: https://orcid.org/0000-0001-7372-9853)
- Adrian J. Verster (ORCID: https://orcid.org/0009-0003-5039-0780)
- Lucas R. Hoffman (ORCID: https://orcid.org/0000-0001-8864-6751)
- David P. Nichols (ORCID: https://orcid.org/0000-0001-8611-7960)
- Steven D. Freedman
- Stephen J. Salipante (ORCID: https://orcid.org/0000-0001-8355-6992)
- George M. Solomon (ORCID: https://orcid.org/0000-0002-2969-5518)
- Jennifer Duong (ORCID: https://orcid.org/0000-0002-5653-2220)
- Kelsi Penewit (ORCID: https://orcid.org/0000-0003-1454-6381)
- Carson J. Miller
- Christopher E. Pope
Institutions
- Beth Israel Deaconess Medical Center (US)
- Statistics Canada (CA)
- Harvard University (US)
- University of Washington (US)
- Cystic Fibrosis Foundation (US)
- Larry Ellison Foundation (US)
- University of Minnesota Children's Hospital (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Journal of Cystic Fibrosis
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1016/j.jcf.2025.05.006
- Citations
- 8
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- Cystic Fibrosis Foundation
- National Institutes of Health